Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial

Romain Guièze (), Loïc Ysebaert, Damien Roos-Weil, Luc-Mathieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran, Aline Clavert, Sophie Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drénou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Anne Quinquenel, Julien Broseus, Valérie Rouille, David Schwartz, Benoit Magnin, Grégory Lazarian, Lauren Véronèse, Marie Antonio, Camille Laurent, Olivier Tournilhac, Bruno Pereira and Pierre Feugier
Additional contact information
Romain Guièze: Service de Thérapie Cellulaire et d’Hématologie Clinique
Loïc Ysebaert: Institut Universitaire du Cancer de Toulouse
Damien Roos-Weil: Sorbonne Université
Luc-Mathieu Fornecker: Institut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg
Emmanuelle Ferrant: Service d’Hématologie Clinique
Lysiane Molina: University Hospital Grenoble Alpes
Thérèse Aurran: Hématologie
Aline Clavert: CHU Angers
Sophie Guibert: CHU Rennes
Anne-Sophie Michallet: Centre Léon Bérard
Alain Saad: Hospital Center of Beziers
Bernard Drénou: CH Mulhouse
Philippe Quittet: CHU Montpellier
Bénédicte Hivert: Groupement des Hôpitaux de l’Institut Catholique de Lille Hôpital St Vincent de Paul
Kamel Laribi: Centre Hospitalier Le Mans
Julie Gay: Centre Hospitalier de la Côte Basque
Anne Quinquenel: University Hospital of Reims, UFR Médecine
Julien Broseus: Service d’Hématologie Biologique, Pôle Laboratoires
Valérie Rouille: French Innovative Leukemia Organization
David Schwartz: French Innovative Leukemia Organization
Benoit Magnin: CHU Clermont-Ferrand
Grégory Lazarian: HUPSSD, Hôpital Avicenne
Lauren Véronèse: Unité de Recherche 7453 (CHELTER)
Marie Antonio: CHU de Clermont-Ferrand
Camille Laurent: Institut Universitaire du Cancer, Centre Hospitalo-Universitaire (CHU) de Toulouse
Olivier Tournilhac: Service de Thérapie Cellulaire et d’Hématologie Clinique
Bruno Pereira: CHU de Clermont-Ferrand
Pierre Feugier: Université de Lorraine

Nature Communications, 2024, vol. 15, issue 1, 1-8

Abstract: Abstract Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 μg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle of R-CHOP, 25 of whom received blinatumomab. After blinatumomab induction, five (20%) patients achieved CR, four (16%) achieved partial response, and six (24%) were stable. Considering the entire strategy, the overall response rate in the full-analysis-set was 46% (n = 18), with CR in 14 (36%) patients. The most common treatment-emergent adverse events of all grades in the blinatumomab-safety-set included fever (36%), anaemia (24%), and lymphopaenia (24%). Cytokine release syndrome (grade 1/2) was observed in 16% and neurotoxicity in 20% of patients. Blinatumomab demonstrated encouraging anti-tumour activity (the trial met its primary endpoint) and acceptable toxicity in patients with RT.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-51264-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-51264-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-51264-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().